FDA authorizes additional omicron Covid booster for seniors and people with weak immune systems

FDA authorizes additional omicron Covid booster for seniors and people with weak immune systems


Sylvester Fisher gets a influenza vaccine from pharmacist Patricia Pernal during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois. The vaccines were being offered along with pneumonia vaccines and the recently authorized COVID-19 booster vaccine, which protects against the original SARS-CoV-2 virus and the more recent omicron variants, BA.4 and BA.5 during the event. (Photo by Scott Olson/Getty Images)

Scott Olson | Getty Images News | Getty Images

The Food and Drug Administration on Tuesday authorized an additional dose of Pfizer and Moderna‘s Covid-19 vaccines targeting the omicron variant for seniors and people with weak immune systems.

Seniors who are 65 years of age or older and who have already received a vaccine targeting the omicron BA.5 subvariant are now eligible to receive another dose at least four months after their last shot, according to the FDA. People with weak immune systems can receive another omicron shot at least two months after their last dose and receive additional shots at the discretion of their doctor.

Children 6 months through 5 years of age who are unvaccinated can now receive the full two-dose series of Moderna’s omicron vaccine. Kids 6 months through 4 years of age can receive three doses of Pfizer’s shot that targets omicron.

Children who are 5 years old can receive either two doses of Moderna or a single dose of Pfizer.

Children under age 5 who have already started their vaccination series with the old Covid vaccines that target the original strain of the virus can receive the omicron shots to finish their course, though how many doses they receive will depend on whether they took Pfizer or Moderna vaccines.

Although the burden of the pandemic has eased substantially, Covid continues to kill more than 1,300 people per week, according to the Centers for Disease Control and Prevention. Some 1,600 people are still hospitalized with Covid daily on average, according to the public health agency.

“Covid-19 continues to be a very real risk for many people, and we encourage individuals to consider staying current with vaccination, including with a bivalent Covid-19 vaccine,” said Dr. Peter Marks, who heads the FDA department responsible for vaccines.

The FDA first authorized the omicron BA.5 shots last August, but that subvariant has long since been displaced by a version of omicron called XBB.1.5. In June, the agency will likely update the variant that the Covid vaccines target, ahead of the fall respiratory virus season.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
Health

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

U.S. President Donald Trump, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, David Sacks, AI & Crypto Czar and Amy Gleason, Acting Administrator, Department of Government Efficiency (DOGE) attend the “Making Health Technology Great Again” event in the East Room […]

Read More
Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Health

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. Nurphoto | Nurphoto | Getty Images Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company’s […]

Read More
Pandemic darlings Moderna, BioNTech are now on two different paths
Health

Pandemic darlings Moderna, BioNTech are now on two different paths

A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024.  Adam Glanzman | Bloomberg | Getty Images The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies are on different paths. Both Moderna and BioNTech helped pioneer mRNA, or […]

Read More